uniQure (NASDAQ: QURE)
uniQure Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
uniQure Company Info
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
News & Analysis
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
Why Shares of uniQure Are Up Thursday
The company announced a reorganization that included layoffs.
Why Shares of uniQure Are Dropping Tuesday
The company is facing being delisted from the S&P 600 Index.
Why uniQure Stock Cratered This Week
An interim analysis for the company's Huntington's disease gene therapy wasn't a hit with investors.
Why uniQure Stock Is Crashing Today
Investors are focusing on the negative parts of the biotech company's interim results.
Why Shares of uniQure Rose 14.61% on Wednesday
A big approval for a gene therapy sent the biotech's stock higher.
Why uniQure Stock Is Crashing Today
The company is temporarily delaying higher-dose procedures of experimental gene therapy AMT-130.
Why uniQure's Stock Price Jumped Today
Its flagship pipeline program just reported a packet of promising safety data.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.